BOREAS
BOREAS: Phase III Trial of Navtemadlin vs Best Available Therapy in Patients With JAK Inhibitor R/R Myelofibrosis

Released: December 11, 2024

Expiration: December 10, 2025

Activity

Progress
1
Course Completed